Skinvive™ by Juvederm® is an innovative facial treatment designed to enhance the smoothness of cheek skin. This unique service is the first and only hyaluronic acid microdroplet injectable explicitly indicated for this purpose. The cream helps the skin retain its natural moisture and softness, improving the smoothness of the cheeks. Suitable for adults over 21, Skinvive™ is an ideal solution for those seeking to rejuvenate their facial appearance. Clinical studies have shown that patients experience high satisfaction with the results, noting improvements in skin glow, hydration, and overall healthiness for up to 6 months following treatment.
The Skinvive™ treatment is tailored for individuals who do not have a history of multiple severe allergies or severe allergic reactions, and it’s particularly crucial to avoid if you are allergic to lidocaine or the proteins used in the product. To ensure optimal results, it’s essential to avoid strenuous exercise, exposure to excessive heat, and alcoholic beverages for the first 24 hours following treatment. While most side effects like redness, swelling, and bruising resolve within a week, patients are advised to consult their physician if these persist.
Adults over 21 without a history of severe allergies, particularly to lidocaine or proteins used in the product.
Patients typically report noticeable skin smoothness and hydration improvements within the first few weeks after treatment.
The effects of the treatment can last up to 6 months, with optimal results maintained through follow-up treatments.
There are a few common side effects, including redness, swelling, and bruising, which usually resolve within a week. Minimal downtime is required.
It is recommended that you don’t exercise strenuously, expose yourself to excessive sun or heat, or consume alcohol within the first 24 hours. Follow any specific instructions provided by your specialist.
The treatment involves intradermal injections to improve cheek skin smoothness, with most patients experiencing minimal discomfort.
